Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Receivables (2020 - 2025)

Historic Receivables for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $22.5 million.

  • Maravai Lifesciences Holdings' Receivables fell 2171.39% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 2171.39%. This contributed to the annual value of $38.5 million for FY2024, which is 2945.7% down from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Receivables is $22.5 million, which was down 2171.39% from $27.9 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Receivables high stood at $138.6 million for Q4 2022, and its period low was $22.5 million during Q3 2025.
  • Moreover, its 5-year median value for Receivables was $54.6 million (2023), whereas its average is $68.8 million.
  • Its Receivables has fluctuated over the past 5 years, first surged by 13033.44% in 2021, then plummeted by 6060.93% in 2023.
  • Over the past 5 years, Maravai Lifesciences Holdings' Receivables (Quarter) stood at $117.5 million in 2021, then rose by 17.97% to $138.6 million in 2022, then plummeted by 60.61% to $54.6 million in 2023, then fell by 29.46% to $38.5 million in 2024, then plummeted by 41.49% to $22.5 million in 2025.
  • Its Receivables was $22.5 million in Q3 2025, compared to $27.9 million in Q2 2025 and $28.5 million in Q1 2025.